Tetrahydroquinoline analogues as muscarinic agonists

Patent metadata

Field	Value
Publication number	US-9522906-B2
Application number	US-201414173627-A
Country	US
Kind code	B2
Filing date	Feb 5, 2014
Priority date	Dec 28, 2001
Publication date	Dec 20, 2016
Grant date	Dec 20, 2016

Abstract

The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.

First claim

What is claimed is:

1. A compound of formula (I), and salts and isomers thereof

wherein:
m is 1;
C 3 -C 4 is CH 2 —CR 1 R 9 ;
R 1 is selected from the group consisting of straight- or branched-chain C 1-6 alkylidene substituted with optionally substituted C 1-6 alkoxy, straight- or branched-chain C 1-6 alkoxy substituted with optionally substituted C 3-8 cycloalkyl, ethoxyethyl, straight- or branched-chain C 1-6 heteroalkyl substituted with halogen, straight- or branched-chain C 1-6 haloalkyl optionally substituted with one or more substituents R X , straight- or branched-chain C 1-6 alkyloxyimino optionally substituted with one or more substituents R X , straight- or branched-chain —OC(O)O(CH 2 ) s CH 3 optionally substituted with one or more substituents R X , wherein each R X is separately selected from the group consisting of halogen, hydroxy, straight- or branched-chain optionally substituted C 1-6 alkyl, straight- or branched-chain optionally substituted C 1-6 alkoxy, optionally substituted C 3-8 cycloalkyl, optionally substituted C 3-8 heterocyclyl, and straight- or branched-chain optionally substituted C 1-6 alkylidene, and s is separately selected to be an integer from 1 to 8;
R 9 is hydrogen;
R 2 and R 3 are hydrogen, or selected such that R 2 and R 3 are covalently linked together to form a ring system, wherein the ring system is formed by selecting R 2 , R 3 , m, and C 3 -C 4 such that

wherein R 8 is present 0, 1, or 2 times and is independently selected from the group consisting of optionally substituted C 1-6 alkyl, optionally substituted O—C 1-6 alkyl, halogen, and hydroxy;
each R 4 and each R 5 are separately selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted C 1-6 -alkyl, optionally substituted O—C 1-6 alkyl, optionally substituted aryl-C 1-6 alkyl, and optionally substituted arylheteroalkyl;
L 1 and L 2 are —C(R 6 )═C(R 7 )—;
Y is O; and
X is a biradical —C(R 6 )(R 7 )—O—;
wherein R 6 and R 7 are separately selected from the group consisting of hydrogen, halogen, hydroxy, nitro, cyano, optionally substituted C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, optionally substituted O—C 1-6 -alkyl, optionally substituted O-aryl, optionally substituted O—C 2-6 -alkenyl, and optionally substituted O—C 2-6 -alkynyl.

2. The compound of claim 1 , wherein:
R X is selected from the group consisting of halogen, optionally substituted C 3-8 cycloalkyl, optionally substituted straight- or branched-chain C 1-6 alkyl, and straight- or branched-chain optionally substituted C 1-6 alkoxy.

3. The compound of claim 1 , wherein:
X is —CH 2 O—;
L l and L 2 is —C(R 6 )═C(R 7 )—; and
each R 6 and each R 7 are separately selected from the group consisting of H, halogen, methyl, and methoxy.

4. The compound according to claim 1 , wherein R 1 is selected from the group consisting of:

5. The compound according to claim 4 selected from the group consisting of:

6. The compound according to claim 1 , wherein the compound is 4-(3 -(3 -(2-ethoxyethyl)-8-azabicyclo [3.2.1]octan-8-yl)-2-methylpropyl)-2H-benzo[b][1,4]oxazin-3 (4H)-one, and salts and isomers thereof.

7. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

8. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt, or ester thereof.

9. A method of treating or alleviating the symptoms associated with a disorder in a mammal, comprising the administration of an effective amount of at least one compound according to claim 1 , wherein the disorder is selected from the group consisting of cognitive impairment, forgetfulness, confusion, memory loss, attentional deficits, deficits in visual perception, depression, pain, sleep disorders, psychosis, increased intraocular pressure, Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Downs Syndrome, Pick disease, dementia, clinical depression, age-related cognitive decline, attention-deficit disorder, sudden infant death syndrome, and glaucoma.

10. The method according to claim 9 , wherein the disease or disorder is selected from the group consisting of increase intraocular pressure and glaucoma.

Assignees

• Acadia Pharm Inc

Inventors

• Skjaerbaek Niels
• Koch Kristian Norup
• Friberg Bo Lennart Mikael
• Tolf Bo-Ragnar

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• A61P27/06

  Antiglaucoma agents or miotics · CPC title